OTTAWA — Well being Canada has permitted Paxlovid, Pfizer’s oral antiviral therapy for COVID-19 that has been touted as a method to ease strain on health-care programs overburdened by rising case counts.
In response to an authorization posted on the regulator’s internet web page Monday morning, the therapy has been permitted for adults with gentle to average types of the sickness who’re at excessive danger of growing extra extreme outcomes.
As a result of security and efficacy information was not submitted to Well being Canada on using the drug on youthful age teams, Paxlovid has not been permitted for pediatric sufferers.
The tablet can be not permitted as a place to begin for therapy for these requiring hospitalization for extreme or crucial COVID-19 instances. It can’t be used as a preventative measure earlier than or after publicity to COVID-19, nor can it’s taken for longer than 5 consecutive days.
Paxlovid works by stopping the virus that causes COVID-19 from replicating itself and invading wholesome cells. The drug is a mix of the Pfizer antiviral Nirmatrelvir and the antiretroviral Ritonavir, a drugs used to deal with HIV.
Well being Canada acquired an utility for approval of the antiviral on Dec. 1. The federal authorities has already signed a cope with Pfizer for a million programs of the therapy.
JOIN THE CONVERSATION